Edgewise Therapeutics (EWTX) News Today $27.07 -0.03 (-0.11%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$27.16 +0.09 (+0.35%) As of 02/21/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 5.9% - Here's WhyEdgewise Therapeutics (NASDAQ:EWTX) Shares Up 5.9% - Time to Buy?February 21 at 2:35 PM | marketbeat.comEdgewise Therapeutics (EWTX) to Release Earnings on ThursdayEdgewise Therapeutics (NASDAQ:EWTX) will be releasing earnings before the market opens on Thursday, February 27.February 20 at 1:42 AM | marketbeat.comShould You Invest in Edgewise Therapeutics (EWTX)?February 19 at 4:21 PM | msn.com10,316 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by AlphaCentric Advisors LLCAlphaCentric Advisors LLC bought a new position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 10,316 shares of the company's stock, valued at approximately $275,000. Several othFebruary 17, 2025 | marketbeat.comdgewise Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorganFebruary 14, 2025 | markets.businessinsider.comJPMorgan lifts Edgewise Therapeutics target to $45February 14, 2025 | msn.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by abrdn plcabrdn plc cut its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 30.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 178,043 shares of the company's stock after selling 78,602 shares duringFebruary 10, 2025 | marketbeat.comEdgewise Therapeutics chief business officer sells $300,300 in stockFebruary 8, 2025 | msn.comEdgewise Therapeutics chief scientific officer sells $276,776 in stockFebruary 8, 2025 | msn.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Alan J. Russell Sells 1,200 SharesFebruary 8, 2025 | insidertrades.comInsider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Sells 1,200 Shares of StockEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) insider Alan J. Russell sold 1,200 shares of the firm's stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $30.13, for a total value of $36,156.00. Following the transaction, the insider now owns 14,863 shares in the company, valued at approximately $447,822.19. This trade represents a 7.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.February 7, 2025 | marketbeat.comInsider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CEO Sells 8,636 Shares of StockEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CEO Kevin Koch sold 8,636 shares of the company's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $30.03, for a total value of $259,339.08. Following the completion of the sale, the chief executive officer now owns 14,478 shares of the company's stock, valued at $434,774.34. This represents a 37.36 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.February 7, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Down 7.1% - Here's WhyEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 7.1% - What's Next?February 7, 2025 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of "Moderate Buy" by AnalystsEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buyFebruary 5, 2025 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest UpdateEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 6,140,000 shares, an increase of 8.9% from the December 31st total of 5,640,000 shares. Approximately 9.8% of the shares of the stock are sold short. Based on an average daily volume of 837,700 shares, the days-to-cover ratio is presently 7.3 days.February 2, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up - What's Next?Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up - Here's WhyJanuary 31, 2025 | marketbeat.comJoanne M. Donovan Sells 25,000 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) StockEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne M. Donovan sold 25,000 shares of the company's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $27.63, for a total transaction of $690,750.00. Following the completion of the sale, the chief marketing officer now directly owns 16,358 shares of the company's stock, valued at approximately $451,971.54. This trade represents a 60.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.January 30, 2025 | marketbeat.comMoody Aldrich Partners LLC Acquires 36,775 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Moody Aldrich Partners LLC boosted its stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 24.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 187,January 29, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Up 7.1% - Time to Buy?Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Up 7.1% - Time to Buy?January 24, 2025 | marketbeat.comWhy Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now?January 23, 2025 | msn.comEdgewise Therapeutics reshuffles executive teamJanuary 22, 2025 | msn.comEdgewise Therapeutics promotes Behrad Derakhshan to COOJanuary 22, 2025 | markets.businessinsider.comEdgewise Therapeutics names new COOJanuary 22, 2025 | msn.comStifel Initiates Coverage of Edgewise Therapeutics (EWTX) with Hold RecommendationJanuary 22, 2025 | msn.comEdgewise rated as a new Hold at Stifel on a balanced risk-reward setupJanuary 22, 2025 | seekingalpha.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - Should You Sell?Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - Here's WhyJanuary 22, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Now Covered by Analysts at Stifel NicolausStifel Nicolaus assumed coverage on Edgewise Therapeutics in a report on Wednesday. They issued a "hold" rating and a $30.00 price objective for the company.January 22, 2025 | marketbeat.comEdgewise Therapeutics initiated with a Hold at StifelJanuary 22, 2025 | markets.businessinsider.comCautious Hold Rating for Edgewise Therapeutics Amid Uncertain Differentiation and EfficacyJanuary 22, 2025 | markets.businessinsider.comShort Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Rises By 8.9%Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 6,140,000 shares, a growth of 8.9% from the December 15th total of 5,640,000 shares. Approximately 9.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 837,700 shares, the days-to-cover ratio is presently 7.3 days.January 19, 2025 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by JPMorgan Chase & Co.JPMorgan Chase & Co. lifted its holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 146.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 158,506 shares of the company's stock after buying an additional 94,147 shares duriJanuary 18, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 6.1% - Time to Sell?Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 6.1% - Time to Sell?January 16, 2025 | marketbeat.comEdgewise Therapeutics: Strategic Positioning and Promising Clinical Advancements Support Buy RatingJanuary 15, 2025 | markets.businessinsider.comPiper Sandler Remains a Buy on Edgewise Therapeutics (EWTX)January 15, 2025 | markets.businessinsider.comTruist Financial Remains a Buy on Edgewise Therapeutics (EWTX)January 15, 2025 | markets.businessinsider.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Up 7.4% - What's Next?Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 7.4% - Still a Buy?January 14, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Edgewise Therapeutics (EWTX) and Avadel Pharmaceuticals (AVDL)January 13, 2025 | markets.businessinsider.comEdgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025January 13, 2025 | stockhouse.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Buy" from AnalystsEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has earned an average recommendation of "Buy" from the six analysts that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month price target among brokerages thaJanuary 11, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - Here's What HappenedEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - Here's What HappenedJanuary 6, 2025 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Alan J. Russell Sells 100,000 SharesJanuary 1, 2025 | insidertrades.comAlan J. Russell Sells 100,000 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) StockEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) insider Alan J. Russell sold 100,000 shares of the company's stock in a transaction on Monday, December 30th. The stock was sold at an average price of $27.37, for a total transaction of $2,737,000.00. Following the completion of the transaction, the insider now directly owns 14,863 shares of the company's stock, valued at $406,800.31. This represents a 87.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.December 31, 2024 | marketbeat.comEdgewise: Remains A Buy After Latest Becker Muscular Dystrophy DataDecember 31, 2024 | seekingalpha.comFranklin Resources Inc. Acquires 20,674 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Franklin Resources Inc. boosted its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 84.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,223 shares of the company's stock afDecember 29, 2024 | marketbeat.comMarc Semigran Sells 29,709 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) StockEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) insider Marc Semigran sold 29,709 shares of the business's stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $29.69, for a total value of $882,060.21. Following the sale, the insider now owns 6,716 shares of the company's stock, valued at $199,398.04. The trade was a 81.56 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.December 27, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 2.5% - Here's What HappenedEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 2.5% - Time to Sell?December 24, 2024 | marketbeat.comGeode Capital Management LLC Has $42.70 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Geode Capital Management LLC cut its holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 4.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,599,535 shares of the company's stock after selling 73,118 shares durDecember 24, 2024 | marketbeat.comBarclays PLC Increases Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Barclays PLC raised its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 291.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 119,350 shares of the company's stock afDecember 24, 2024 | marketbeat.comState Street Corp Has $44.98 Million Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)State Street Corp boosted its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 1.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,685,115 shares of the company's sDecember 20, 2024 | marketbeat.comLeerink Partnrs Issues Optimistic Estimate for EWTX EarningsEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2026 earnings per share (EPS) estimates for shares of Edgewise Therapeutics in a research note issued on Monday, December 16th. Leerink Partnrs analyst J. Schwartz now anticipates thatDecember 19, 2024 | marketbeat.com Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address EWTX Media Mentions By Week EWTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EWTX News Sentiment▼0.470.60▲Average Medical News Sentiment EWTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EWTX Articles This Week▼44▲EWTX Articles Average Week Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Qiagen News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Revolution Medicines News Today Legend Biotech News Today BridgeBio Pharma News Today Axsome Therapeutics News Today Blueprint Medicines News Today Telix Pharmaceuticals Limited American Depositary Shares News Today Elanco Animal Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EWTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EWTX Stock Alerts